Ultragenyx Pharmaceutical (RARE) Net Cash Flow Growth (1y) (2014 - 2026)
Ultragenyx Pharmaceutical (RARE) Net Cash Flow Growth (1y) (2014 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | -88.82% |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 301.06% |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 453.08% |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | -125.22% |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | - |
| 10 | Ultragenyx Pharmaceutical | 2.71 Bn | 2.30 Bn | 106.00 Mn | -436.61% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -436.61% |
| Dec 31, 2025 | 749.94% |
| Sep 30, 2025 | 107.78% |
| Jun 30, 2025 | -87.53% |
| Mar 31, 2025 | 52.42% |
| Dec 31, 2024 | -81.25% |
| Sep 30, 2024 | -1,068.89% |
| Jun 30, 2024 | 2,164.18% |
| Mar 31, 2024 | -108.17% |
| Dec 31, 2023 | 153.59% |
| Sep 30, 2023 | -112.08% |
| Jun 30, 2023 | 110.08% |
| Mar 31, 2023 | 69.80% |
| Dec 31, 2022 | -358.92% |
| Sep 30, 2022 | 352.72% |
| Jun 30, 2022 | 108.24% |
| Mar 31, 2022 | 53.43% |
| Dec 31, 2021 | -80.87% |
| Sep 30, 2021 | 33.00% |
| Jun 30, 2021 | -353.83% |